Suppr超能文献

SATB1 过表达通过抑制 p21 促进皮肤 CD30+淋巴组织增生性疾病中恶性 T 细胞的增殖。

SATB1 overexpression promotes malignant T-cell proliferation in cutaneous CD30+ lymphoproliferative disease by repressing p21.

机构信息

Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China;

Department of Dermatovenereology, West China Hospital, Sichuan University, Chengdu, Sichuan, China;

出版信息

Blood. 2014 May 29;123(22):3452-61. doi: 10.1182/blood-2013-10-534693. Epub 2014 Apr 18.

Abstract

Cutaneous CD30(+) lymphoproliferative disease (CD30(+)LPD), characterized by the presence of CD30(+) anaplastic large T cells, comprises the second most common group of cutaneous T-cell lymphoma (CTCL). However, little is known about the pathobiology of the CD30(+) lymphoma cells, as well as the mechanisms of disease progression. Here we report that Special AT-rich region binding protein 1 (SATB1), a thymocyte specific chromatin organizer, is over-expressed in CD30(+) lymphoma cells in most CD30(+)LPDs, and its expression is upregulated during disease progression. Our findings show that SATB1 silencing in CD30(+)LPD cells leads to G1 cell cycle arrest mediated by p21 activation. Using chromatin immunoprecipitation, luciferase assays, and mutational analysis, we demonstrate that SATB1 directly regulates the transcription of p21 in a p53-independent manner. Moreover, DNA demethylation on a specific CpG-rich region of the SATB1 promoter is associated with the upregulation of SATB1 during disease progression. These experiments define a novel SATB1-p21 pathway in malignant CD30(+) T lymphocytes, which provides novel molecular insights into the pathogenesis of CD30(+)LPDs and possibly leads to new therapies.

摘要

皮肤 CD30(+)淋巴增生性疾病(CD30(+)LPD),其特征在于存在 CD30(+)间变性大 T 细胞,构成了第二类最常见的皮肤 T 细胞淋巴瘤(CTCL)。然而,对于 CD30(+)淋巴瘤细胞的病理生物学,以及疾病进展的机制,人们知之甚少。在这里,我们报告称,富含特殊 AT 的区域结合蛋白 1(SATB1),一种胸腺细胞特异性染色质组织者,在大多数 CD30(+)LPD 中的 CD30(+)淋巴瘤细胞中过度表达,并且其表达在疾病进展过程中上调。我们的研究结果表明,SATB1 在 CD30(+)LPD 细胞中的沉默会导致 p21 激活介导的 G1 细胞周期停滞。通过染色质免疫沉淀、荧光素酶测定和突变分析,我们证明 SATB1 以一种不依赖 p53 的方式直接调节 p21 的转录。此外,在 SATB1 启动子上特定富含 CpG 的区域的 DNA 去甲基化与疾病进展过程中 SATB1 的上调有关。这些实验定义了恶性 CD30(+)T 淋巴细胞中 SATB1-p21 通路的新机制,为 CD30(+)LPD 的发病机制提供了新的分子见解,并可能导致新的治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验